- Home
- TGTX vs KNF Comparison
TGTX vs KNF Comparison
Compare TGTX & KNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- KNF
- Stock Information
- Founded
- TGTX 1993
- KNF 1917
- Country
- TGTX United States
- KNF United States
- Employees
- TGTX N/A
- KNF N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- KNF
- Sector
- TGTX Health Care
- KNF
- Exchange
- TGTX Nasdaq
- KNF Nasdaq
- Market Cap
- TGTX 4.2B
- KNF 4.6B
- IPO Year
- TGTX 1995
- KNF N/A
- Fundamental
- Price
- TGTX $32.18
- KNF $78.96
- Analyst Decision
- TGTX Strong Buy
- KNF Strong Buy
- Analyst Count
- TGTX 4
- KNF 6
- Target Price
- TGTX $42.50
- KNF $114.33
- AVG Volume (30 Days)
- TGTX 2.0M
- KNF 620.8K
- Earning Date
- TGTX 11-03-2025
- KNF 11-03-2025
- Dividend Yield
- TGTX N/A
- KNF N/A
- EPS Growth
- TGTX N/A
- KNF N/A
- EPS
- TGTX 0.36
- KNF 2.71
- Revenue
- TGTX $454,069,000.00
- KNF $2,949,740,000.00
- Revenue This Year
- TGTX $82.58
- KNF $11.80
- Revenue Next Year
- TGTX $44.99
- KNF $5.95
- P/E Ratio
- TGTX $89.78
- KNF $29.05
- Revenue Growth
- TGTX 30.96
- KNF 2.64
- 52 Week Low
- TGTX $21.16
- KNF $74.51
- 52 Week High
- TGTX $46.48
- KNF $108.83
- Technical
- Relative Strength Index (RSI)
- TGTX 57.80
- KNF 40.96
- Support Level
- TGTX $31.34
- KNF $77.46
- Resistance Level
- TGTX $32.57
- KNF $81.72
- Average True Range (ATR)
- TGTX 1.13
- KNF 2.71
- MACD
- TGTX 0.54
- KNF -0.55
- Stochastic Oscillator
- TGTX 76.10
- KNF 17.19
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About KNF Knife Riv Holding Co.
Knife River Holding Co is an aggregates-led construction materials and contracting services provider. Its segments include Pacific, Northwest, Mountain, North Central, South, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.